Vanguard Group Inc Mi Nk Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INKT
# of Institutions
34Shares Held
901KCall Options Held
0Put Options Held
0-
Longbow Finance Sa Lutry, V8167KShares$131,6660.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny128KShares$100,9940.0% of portfolio
-
Geode Capital Management, LLC Boston, MA96.3KShares$76,1140.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$68,8840.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL50.7KShares$40,0460.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $26.7M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...